{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-21-000043","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.029250+00:00","generated_at":"2026-06-28T12:57:46.854945+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prothena reports Q3 net income of $109.2M vs loss; revenue $139.2M on partner payments","bullets":["Q3 net income $109.2M ($2.13 diluted EPS) vs net loss $30.6M a year ago; 9-month net income $100.2M.","Revenue $139.2M, driven by $78.5M BMS option for PRX005 US license and $60.7M IP sale to Novo Nordisk.","Cash, equivalents and restricted cash $601.5M at Sept 30, 2021; no debt.","Updated FY2021 guidance: year-end cash ~$575M, net cash from ops/investing $85-95M, net income $50-60M.","Appointed Tran Nguyen as CFO and Chief Strategy Officer; Brandon Smith as COO."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-21-000043","json":"https://secwatch.observer/filing/0001559053-21-000043.json","markdown":"https://secwatch.observer/filing/0001559053-21-000043.md","text":"https://secwatch.observer/filing/0001559053-21-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905321000043/0001559053-21-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905321000043/prta-20211104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T12:57:46.854945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}